{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination with R-CHP Versus R- CHOP in Participant With Previously Untreated Diffuse Large B- Cell Lymphoma (DLDCL) (waveLINE-010)","item":"https:\/\/www.regionalcancercare.org\/trials\/a-randomized-open-label-multicenter-phase-3-study-of-zilovertamab-vedotin-mk-2140-in-combination-with-r-chp-versus-r-chop-in-participant-with-previously-untreated-diffuse-large-b-cell-lymphoma\/#breadcrumbitem"}]}